Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: R-Pharm Clear all
Completed Phase 1 Interventional Results available

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

NCT00162136
View directory record Official record
Conditions
Solid Malignancies
Interventions
Ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • New Brunswick, New Jersey • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

NCT00422097
View directory record Official record
Conditions
Cancer
Interventions
Ixabepilone, 5 mg/d, Ixabepilone, 10 mg/d, Ixabepilone, 15 mg/d, Ixabepilone, 20 mg/d, Ixabepilone, 25 mg/d, Ixabepilone, 30 mg/d, Ixabepilone, 25 mg, with famotidine, Ixabepilone, 25 mg, with food
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

NCT00723957
View directory record Official record
Conditions
Advanced/Metastatic Non-Small Cell Lung Cancer
Interventions
Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6)
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
La Jolla, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 25, 2026, 5:30 PM EDT
Terminated Phase 1 Interventional Results available

Phase 1 Trial of Oral Ixabepilone

NCT00632424
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Ixabepilone (oral formulation)
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stanford, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00082433
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer

NCT00593827
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Suspended Phase 2Phase 3 Interventional

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

NCT05107934
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 25, 2026, 5:30 PM EDT
Terminated Phase 1 Interventional Results available

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT00634088
View directory record Official record
Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg, Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone + Lapatinib + Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

NCT00546364
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2, Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2, Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Tuscaloosa, Alabama • La Jolla, California • Southington, Connecticut + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

NCT00383149
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ixabepilone, Cetuximab
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

NCT03093155
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Ixabepilone, Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

NCT00080262
View directory record Official record
Conditions
Breast Cancer, Metastases
Interventions
Ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
La Verne, California • Meriden, Connecticut • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional

Ixabepilone Administered as an Enteric Coated Formulation.

NCT00309049
View directory record Official record
Conditions
Cancer
Interventions
Ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 1 Interventional Results available

Phase I Combination Ixabepilone + Cisplatin

NCT00832117
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ixabepilone, Cisplatin
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New Brunswick, New Jersey • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00080301
View directory record Official record
Conditions
Breast Cancer, Metastases
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • San Francisco, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy

NCT00035516
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
Epothilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Sacramento, California • Miami Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Not listed Phase 1 Interventional

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

NCT00049244
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine, ixabepilone
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 1 Interventional Results available

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

NCT00207090
View directory record Official record
Conditions
Advanced Solid Tumors, Neoplasms
Interventions
ixabepilone, Rifampin
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

NCT00370552
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg, Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg, Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Burbank, California • La Verne, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

NCT03120949
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
71
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 25, 2026, 5:30 PM EDT
Withdrawn Phase 2 Interventional

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

NCT04213274
View directory record Official record
Conditions
Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions
80 mg RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 25, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mg, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2024 · Synced Sep 25, 2026, 5:30 PM EDT